Rupatadine-d6 (D-tartrate)

Rupatadine-d6 (D-tartrate) is deuterated labeled Rupatadine (HY-13511) . Rupatadine (UR-12592) is a potent, orally active and long-lasting dual PAF/H1 antagonist, with Kis of 0.55 μM and 0.1 μM, respectively. Rupatadine can be used for the research of allergic rhinitis and urticaria[1][2][3].

Product Specifications

Product Name Alternative

UR-12592-d6

UNSPSC

12352005

Target

Autophagy; Histamine Receptor; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Autophagy; GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling; Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Solubility

10 mM in DMSO

Smiles

ClC1=CC2=C(C=C1)/C(C3=C(CC2)C=CC=N3)=C4C([2H])C([2H])N(C([2H])([2H])C5=CC(C)=CN=C5)C([2H])C\4[2H].O[C@H](C(O)=O)[C@H](O)C(O)=O

Molecular Formula

C30H26D6ClN3O6

Molecular Weight

572.08

References & Citations

[1]Merlos M, et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF) . J Pharmacol Exp Ther. 1997 Jan;280 (1) :114-21.|[2]Lv XX, et al. Rupatadine protects against pulmonary fibrosis by attenuating PAF-mediated senescence in rodents. PLoS One. 2013 Jul 15;8 (7) :e68631.|[3]Queralt M, et al. In vitro inhibitory effect of rupatadine on histamine and TNF-alpha release from dispersed canine skin mast cells and the human mast cell line HMC-1. Inflamm Res. 2000 Jul;49 (7) :355-60.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.